Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
Abstract We extended our previous observations with other tumor models to study seven ovarian tumor cell lines—OVCAR3, OVCAR4, OVCAR8, SKOV3, Kuramochi, OAW28, and CaOV3. We found that NK cells targeted and killed poorly differentiated OVCAR8 and CAOV3; these two tumor lines express lower MHC-class I and higher CD44 surface receptors. OVCAR3 and OVCAR4 were more resistant to NK cell-mediated cytotoxicity, and SKOV3, Kuramochi and OAW28 had intermediate sensitivity to NK cell-mediated cytotoxicity, likely representing well-differentiated and moderately differentiated ovarian tumor cell lines, respectively. Similar trends were observed for secretion of IFN-γ by the NK cells when co-cultured with different ovarian tumor cell lines. Treatment with both IFN-γ and TNF-α upregulated MHC-class I in all ovarian tumor cell lines and resulted in tumor resistance to NK cell-mediated cytotoxicity and decreased secretion of IFN-γ in co-cultures of NK cells with tumors cells with the exception of OVCAR8 and CAOV3 which did not upregulate MHC-class I and remained sensitive to NK cell-mediated cytotoxicity and increased secretion of IFN-γ when co-cultured with NK cells. Similarly, treatment with NK cell supernatants induced resistance to NK cell-mediated cytotoxicity in OVCAR4 but not in OVCAR8, and the resistance to killing was correlated with the increased surface expression of MHC-class I in OVCAR4 but not in OVCAR8. In addition, OVCAR4 was found to be carboplatin sensitive before and after treatment with IFN-γ and NK cell supernatants, whereas OVCAR8 remained carboplatin resistant with and without treatment with IFN-γ and NK cell supernatants. Overall, sensitivity to NK cell-mediated killing correlated with the levels of tumor differentiation and aggressiveness, and more importantly, poorly differentiated ovarian tumors were unable to upregulate MHC-class I under the activating conditions for MHC-class I, a feature that was not seen in other tumor models and may likely be specific to ovarian tumors. Such tumors may also pose a significant challenge in elimination by the T cells; however, NK cells are capable of targeting such tumors and can be exploited to eliminate these tumors in immunotherapeutic strategies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Cancer immunology immunotherapy - 71(2022), 12 vom: 04. Mai, Seite 2929-2941 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chovatiya, Nishant [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Chemotherapeutic drugs |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00262-022-03192-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048392618 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048392618 | ||
| 003 | DE-627 | ||
| 005 | 20230519223755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221026s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-022-03192-7 |2 doi | |
| 035 | |a (DE-627)SPR048392618 | ||
| 035 | |a (SPR)s00262-022-03192-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chovatiya, Nishant |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Abstract We extended our previous observations with other tumor models to study seven ovarian tumor cell lines—OVCAR3, OVCAR4, OVCAR8, SKOV3, Kuramochi, OAW28, and CaOV3. We found that NK cells targeted and killed poorly differentiated OVCAR8 and CAOV3; these two tumor lines express lower MHC-class I and higher CD44 surface receptors. OVCAR3 and OVCAR4 were more resistant to NK cell-mediated cytotoxicity, and SKOV3, Kuramochi and OAW28 had intermediate sensitivity to NK cell-mediated cytotoxicity, likely representing well-differentiated and moderately differentiated ovarian tumor cell lines, respectively. Similar trends were observed for secretion of IFN-γ by the NK cells when co-cultured with different ovarian tumor cell lines. Treatment with both IFN-γ and TNF-α upregulated MHC-class I in all ovarian tumor cell lines and resulted in tumor resistance to NK cell-mediated cytotoxicity and decreased secretion of IFN-γ in co-cultures of NK cells with tumors cells with the exception of OVCAR8 and CAOV3 which did not upregulate MHC-class I and remained sensitive to NK cell-mediated cytotoxicity and increased secretion of IFN-γ when co-cultured with NK cells. Similarly, treatment with NK cell supernatants induced resistance to NK cell-mediated cytotoxicity in OVCAR4 but not in OVCAR8, and the resistance to killing was correlated with the increased surface expression of MHC-class I in OVCAR4 but not in OVCAR8. In addition, OVCAR4 was found to be carboplatin sensitive before and after treatment with IFN-γ and NK cell supernatants, whereas OVCAR8 remained carboplatin resistant with and without treatment with IFN-γ and NK cell supernatants. Overall, sensitivity to NK cell-mediated killing correlated with the levels of tumor differentiation and aggressiveness, and more importantly, poorly differentiated ovarian tumors were unable to upregulate MHC-class I under the activating conditions for MHC-class I, a feature that was not seen in other tumor models and may likely be specific to ovarian tumors. Such tumors may also pose a significant challenge in elimination by the T cells; however, NK cells are capable of targeting such tumors and can be exploited to eliminate these tumors in immunotherapeutic strategies. | ||
| 650 | 4 | |a Ovarian cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IFN-γ |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TNF-α |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytotoxicity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Differentiation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapeutic drugs |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kaur, Kawaljit |4 aut | |
| 700 | 1 | |a Huerta-Yepez, Sara |4 aut | |
| 700 | 1 | |a Chen, Po-Chun |4 aut | |
| 700 | 1 | |a Neal, Adam |4 aut | |
| 700 | 1 | |a DiBernardo, Gabriella |4 aut | |
| 700 | 1 | |a Gumrukcu, Serhat |4 aut | |
| 700 | 1 | |a Memarzadeh, Sanaz |4 aut | |
| 700 | 1 | |a Jewett, Anahid |0 (orcid)0000-0002-7840-1176 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Berlin : Springer, 1976 |g 71(2022), 12 vom: 04. Mai, Seite 2929-2941 |w (DE-627)SPR003214370 |w (DE-600)1458489-X |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2022 |g number:12 |g day:04 |g month:05 |g pages:2929-2941 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00262-022-03192-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2022 |e 12 |b 04 |c 05 |h 2929-2941 | ||